{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:04:13Z","timestamp":1791468253793,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00192-026-06590-y","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:19:37Z","timestamp":1773749977000},"page":"2765-2777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging Urinary Biomarkers for Diagnosis, Phenotyping, and Treatment Monitoring in Female Overactive Bladder: A Systematic Review"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3669-4855","authenticated-orcid":false,"given":"Indranil","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Baines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Izett-Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerald Win","family":"OO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"8","key":"6590_CR1","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00192-024-06029-2","volume":"36","author":"L Zhang","year":"2025","unstructured":"Zhang L, Cai N, Mo L, Tian X, Liu H, Yu B. Global prevalence of overactive bladder: a systematic review and meta-analysis. Int Urogynecol J. 2025;36(8):1547\u201366. https:\/\/doi.org\/10.1007\/s00192-024-06029-2.","journal-title":"Int Urogynecol J"},{"issue":"2","key":"6590_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.18553\/jmcp.2014.20.2.130","volume":"20","author":"KS Coyne","year":"2014","unstructured":"Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20(2):130\u201340. https:\/\/doi.org\/10.18553\/jmcp.2014.20.2.130.","journal-title":"J Manag Care Pharm"},{"issue":"8","key":"6590_CR3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/nau.25028","volume":"41","author":"N Y\u0131ld\u0131z","year":"2022","unstructured":"Y\u0131ld\u0131z N, \u00d6zl\u00fc A. Factors predicting the treatment success of bladder training for urgency urinary incontinence. Neurourol Urodyn. 2022;41(8):1809\u201316. https:\/\/doi.org\/10.1002\/nau.25028.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"6590_CR4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3122\/jabfm.2023.230471R1","volume":"37","author":"R Al-Dossari","year":"2024","unstructured":"Al-Dossari R, Kalra M, Adkison J, Nguyen BM. Non-surgical management of urinary incontinence. J Am Board Fam Med. 2024;37(5):909\u201318. https:\/\/doi.org\/10.3122\/jabfm.2023.230471R1.","journal-title":"J Am Board Fam Med"},{"issue":"5","key":"6590_CR5","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.eururo.2006.04.018","volume":"50","author":"P Reeves","year":"2006","unstructured":"Reeves P, Irwin D, Kelleher C, Milsom I, Kopp Z, Calvert N, et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol. 2006;50(5):1050\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2006.04.018.","journal-title":"Eur Urol"},{"issue":"5","key":"6590_CR6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00192-013-2261-1","volume":"25","author":"JY Yeung","year":"2014","unstructured":"Yeung JY, Eschenbacher MA, Pauls RN. Pain and embarrassment associated with urodynamic testing in women. Int Urogynecol J. 2014;25(5):645\u201350. https:\/\/doi.org\/10.1007\/s00192-013-2261-1.","journal-title":"Int Urogynecol J"},{"issue":"1","key":"6590_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5173\/ceju.2017.1597","volume":"71","author":"P Petros","year":"2018","unstructured":"Petros P. A ligamentous explanation for overactive bladder symptoms as defined by international continence society in the female. Cent Eur J Urol. 2018;71(1):105\u20137. https:\/\/doi.org\/10.5173\/ceju.2017.1597.","journal-title":"Cent Eur J Urol"},{"issue":"6","key":"6590_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","volume":"5","author":"K Strimbu","year":"2010","unstructured":"Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5(6):463\u20136. https:\/\/doi.org\/10.1097\/COH.0b013e32833ed177.","journal-title":"Curr Opin HIV AIDS"},{"issue":"7","key":"6590_CR9","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1002\/nau.23210","volume":"36","author":"W Sheng","year":"2017","unstructured":"Sheng W, Zhang H, Ruth K. Could urinary nerve growth factor be a biomarker for overactive bladder? A meta-analysis. Neurourol Urodyn. 2017;36(7):1703\u201310. https:\/\/doi.org\/10.1002\/nau.23210","journal-title":"Neurourol Urodyn"},{"issue":"10","key":"6590_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.5603\/GP.a2017.0102","volume":"88","author":"A Wr\u00f3bel","year":"2017","unstructured":"Wr\u00f3bel A, Kluz T, Surkont G, Wla\u017alak E, Skorupski P, Filipczak A. Novel biomarkers of overactive bladder syndrome. Ginekol Pol. 2017;88(10):568\u201373. https:\/\/doi.org\/10.5603\/GP.a2017.0102","journal-title":"Ginekol Pol"},{"issue":"12","key":"6590_CR11","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1007\/s00192-021-04945-1","volume":"32","author":"S Tsiapakidou","year":"2021","unstructured":"Tsiapakidou S, Apostolidis A, Pantazis K, Grimbizis GF, Mikos T. The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis. Int Urogynecol J. 2021;32(12):3143\u201355. https:\/\/doi.org\/10.1007\/s00192-021-04945-1","journal-title":"Int Urogynecol J"},{"issue":"1","key":"6590_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4103\/sja.sja_545_23","volume":"18","author":"V Grech","year":"2024","unstructured":"Grech V, Eldawlatly AA. STROBE, CONSORT, PRISMA, MOOSE, STARD, SPIRIT, and other guidelines - overview and application. Saudi J Anaesth. 2024;18(1):137\u201341. https:\/\/doi.org\/10.4103\/sja.sja_545_23","journal-title":"Saudi J Anaesth"},{"issue":"7829","key":"6590_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(7829):889\u201393. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"issue":"10","key":"6590_CR14","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.11124\/JBISRIR-D-19-00099","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Database System Rev Implement Rep. 2020;18(10):2127\u201333. https:\/\/doi.org\/10.11124\/JBISRIR-D-19-00099","journal-title":"JBI Database System Rev Implement Rep"},{"key":"6590_CR15","unstructured":"Wells, George & Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P (2000) The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. https:\/\/ohri.ca\/en\/who-we-are\/core-facilities-and-platforms\/ottawa-methods-centre\/newcastle-ottawa-scale"},{"issue":"5","key":"6590_CR16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00192-024-05809-0","volume":"35","author":"A Beta","year":"2024","unstructured":"Beta A, Giannouli A, Rizos D, Mantzou A, Deligeoroglou E, Bakas P. Nerve growth factor and brain-derived neurotrophic factor as potential biomarkers of mirabegron efficacy in patients with overactive bladder syndrome. Int Urogynecol J. 2024;35(5):789\u201397.","journal-title":"Int Urogynecol J"},{"issue":"3","key":"6590_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030673","volume":"11","author":"J-F Jhang","year":"2023","unstructured":"Jhang J-F, Jiang Y-H, Kuo H-C. Discriminating different bladder and bladder outlet dysfunctions by urinary biomarkers in women with frequency-urgency syndrome. Biomedicines. 2023;11(3):673. https:\/\/doi.org\/10.3390\/biomedicines11030673","journal-title":"Biomedicines"},{"issue":"4","key":"6590_CR18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/SPV.0000000000001316","volume":"29","author":"EC Maetzold","year":"2023","unstructured":"Maetzold EC, Santillan DA, Kenne KA, Bradley CS, Ten Eyck P, Wendt L, et al. Urinary biomarkers and overactive bladder symptoms before and after prolapse surgery. Urogynecology. 2023;29(4):266\u201372. https:\/\/doi.org\/10.1097\/SPV.0000000000001316.","journal-title":"Urogynecology"},{"issue":"3","key":"6590_CR19","first-page":"210","volume":"45","author":"A Covarrubias","year":"2023","unstructured":"Covarrubias A, Tarin T, Kim J. Elevated urinary MMP-9 activity and its correlation with reduced proBDNF\/BDNF ratios in overactive bladder patients. J Urol Res. 2023;45(3):210\u20138.","journal-title":"J Urol Res"},{"issue":"9","key":"6590_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12090820","volume":"12","author":"PG Cammisotto","year":"2022","unstructured":"Cammisotto PG, Mossa AH, Shamout S, Campeau L. Urinary levels of miR-491-5p and miR-592 as potential diagnostic biomarkers in female aging patients with OAB: a pilot study. Metabolites. 2022;12(9):820. https:\/\/doi.org\/10.3390\/metabo12090820","journal-title":"Metabolites"},{"issue":"8","key":"6590_CR21","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1007\/s11255-022-03116-5","volume":"54","author":"P-M Chow","year":"2022","unstructured":"Chow P-M, Kuo H-C. Performance of urinary biomarkers in differentiating dysfunctional voiding in women with overactive bladder syndrome: a prospective pilot study. Int Urol Nephrol. 2022;54(8):2255\u201364.","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"6590_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11040971","volume":"11","author":"K Jankiewicz","year":"2022","unstructured":"Jankiewicz K, Bogusiewicz M, Nowakowski \u0141, Rechberger T, Rogowski A, Miotla P. Urine nerve growth factor may not be useful as a biomarker of overactive bladder in patients with pelvic organ prolapse. J Clin Med. 2022;11(4):971. https:\/\/doi.org\/10.3390\/jcm11040971","journal-title":"J Clin Med"},{"issue":"5","key":"6590_CR23","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s11255-021-02864-0","volume":"53","author":"H Salehi-Pourmehr","year":"2021","unstructured":"Salehi-Pourmehr H, Ghojazadeh M, Jahantabi E, Hajebrahimi S. Diagnostic value of nerve growth factor in detrusor overactivity: a study on women with mixed urinary incontinence. Int Urol Nephrol. 2021;53(5):927\u201334.","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"6590_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.5213\/inj.2040366.183","volume":"24","author":"G Ghoniem","year":"2020","unstructured":"Ghoniem G, Farhan B, Csuka D, Zaldivar F. Potential role of monocyte chemoattractant protein-1 in monitoring disease progression and response to treatment in overactive bladder patients. Int Neurourol J. 2020;24(4):341\u20138. https:\/\/doi.org\/10.5213\/inj.2040366.183.","journal-title":"Int Neurourol J"},{"issue":"7","key":"6590_CR25","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1002\/nau.24487","volume":"39","author":"MP Rada","year":"2020","unstructured":"Rada MP, Ciortea R, M\u0103lu\u021ban AM, Doumouchtsis SK, Bucuri CE, Clim A, et al. The profile of urinary biomarkers in overactive bladder. Neurourol Urodyn. 2020;39(7):2305\u201313. https:\/\/doi.org\/10.1002\/nau.24487.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"6590_CR26","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1113\/EP088450","volume":"105","author":"S Firouzmand","year":"2020","unstructured":"Firouzmand S, Young JS. A pilot study to investigate the associations of urinary concentrations of NO, ATP, and derivatives with overactive bladder symptom severity. Exp Physiol. 2020;105(6):932\u20139. https:\/\/doi.org\/10.1113\/EP088450.","journal-title":"Exp Physiol"},{"issue":"1","key":"6590_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59973-6","volume":"10","author":"S Firouzmand","year":"2020","unstructured":"Firouzmand S, Ajori L, Young JS. New participant stratification and combination of urinary biomarkers and confounders could improve diagnostic accuracy for overactive bladder. Sci Rep. 2020;10(1):3085. https:\/\/doi.org\/10.1038\/s41598-020-59973-6","journal-title":"Sci Rep"},{"issue":"8","key":"6590_CR28","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s00345-020-03422-6","volume":"39","author":"AH Mossa","year":"2021","unstructured":"Mossa AH, Cammisotto PG, Shamout S, Campeau L. Imbalance of nerve growth factor metabolism in aging women with overactive bladder syndrome. World J Urol. 2021;39(8):2055\u201363. https:\/\/doi.org\/10.1007\/s00345-020-03422-6.","journal-title":"World J Urol"},{"issue":"10","key":"6590_CR29","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/SPV.0000000000000639","volume":"26","author":"D Sheyn","year":"2020","unstructured":"Sheyn D, Hijaz AK, Hazlett FE, Dawodu K, El-Nashar S, Mangel JM, et al. Evaluation of urine choline levels in women with and without overactive bladder syndrome. Female Pelvic Med Reconstr Surg. 2020;26(10):644\u20138. https:\/\/doi.org\/10.1097\/SPV.0000000000000639.","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"3","key":"6590_CR30","first-page":"431","volume":"51","author":"B Farhat","year":"2019","unstructured":"Farhat B, Chang H, Ahmed A, Zaldivar F, Ghoniem G. Characterisation of urinary monocyte chemoattractant protein 1: potential biomarker for patients with overactive bladder. Int Urol Nephrol. 2019;51(3):431\u20138.","journal-title":"Int Urol Nephrol"},{"issue":"9","key":"6590_CR31","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1097\/CM9.0000000000000214","volume":"132","author":"X-J Tian","year":"2019","unstructured":"Tian X-J, Liu C, Liu K, Tang S-Y. Urinary biomarkers of overactive bladder. Chin Med J. 2019;132(9):1104\u20136. https:\/\/doi.org\/10.1097\/CM9.0000000000000214.","journal-title":"Chin Med J"},{"issue":"6","key":"6590_CR32","first-page":"590.e1","volume":"219","author":"HE Richter","year":"2018","unstructured":"Richter HE, Moalli P, Amundsen CL, Malykhina AP, Wallace D, Rogers R, et al. Urinary biomarkers in women with refractory urgency urinary incontinence randomized to sacral neuromodulation versus onabotulinumtoxinA compared to controls. Am J Obstet Gynecol. 2018;219(6):590.e1-590.e7.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"6590_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5213\/inj.1732734.403","volume":"21","author":"YS Suh","year":"2017","unstructured":"Suh YS, Ko KJ, Kim TH, Lee HS, Sung HH, Cho WJ, et al. Potential biomarkers for diagnosis of overactive bladder patients: urinary nerve growth factor, prostaglandin E2, and adenosine triphosphate. Int Neurourol J. 2017;21(3):171\u20137. https:\/\/doi.org\/10.5213\/inj.1732734.403","journal-title":"Int Neurourol J"},{"issue":"1","key":"6590_CR34","doi-asserted-by":"publisher","first-page":"F28","DOI":"10.1152\/ajprenal.00580.2015","volume":"311","author":"E Ma","year":"2016","unstructured":"Ma E, Vetter J, Bliss L, Lai HH, Mysorekar IU, Jain S. A multiplexed analysis approach identifies new associations of inflammatory proteins in patients with overactive bladder. Am J Physiol Renal Physiol. 2016;311(1):F28-34. https:\/\/doi.org\/10.1152\/ajprenal.00580.2015.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"6590_CR35","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/nau.23011","volume":"36","author":"JF Pennycuff","year":"2017","unstructured":"Pennycuff JF, Schutte SC, Hudson CO, Karp DR, Malykhina AP, Northington GM. Urinary neurotrophic peptides in postmenopausal women with and without overactive bladder. Neurourol Urodyn. 2017;36(3):740\u20134. https:\/\/doi.org\/10.1002\/nau.23011.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"6590_CR36","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/nau.22939","volume":"36","author":"O Alkis","year":"2015","unstructured":"Alkis O, Zumrutbas AE, Toktas C, Aybek H, Aybek Z. The use of biomarkers in the diagnosis and treatment of overactive bladder: can we predict the patients who will be resistant to treatment? Neurourol Urodyn. 2015;36(3):390\u20133. https:\/\/doi.org\/10.1002\/nau.22939.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"6590_CR37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00192-015-2864-9","volume":"27","author":"S Ciftci","year":"2016","unstructured":"Ciftci S, Ozkurkcugil C, Yilmaz H, Ustuner M, Yavuz U, Yuksekkaya M, et al. Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder. Int Urogynecol J. 2016;27(3):445\u201351. https:\/\/doi.org\/10.1007\/s00192-015-2864-9","journal-title":"Int Urogynecol J"},{"issue":"3","key":"6590_CR38","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3349\/ymj.2015.56.3.761","volume":"56","author":"SR Kim","year":"2015","unstructured":"Kim SR, Moon YJ, Kim SK, Bai SW. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome. Yonsei Med J. 2015;56(3):761\u20138. https:\/\/doi.org\/10.3349\/ymj.2015.56.3.761.","journal-title":"Yonsei Med J"},{"issue":"5","key":"6590_CR39","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00192-014-2309-1","volume":"25","author":"SW Kim","year":"2014","unstructured":"Kim SW, Im YJ, Choi HC, Kang HJ, Kim JY, Kim JH. Urinary nerve growth factor correlates with the severity of urgency and pain. Int Urogynecol J. 2014;25(5):657\u201364. https:\/\/doi.org\/10.1007\/s00192-014-2309-1.","journal-title":"Int Urogynecol J"},{"issue":"1","key":"6590_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80131-5","volume":"11","author":"Y-H Jiang","year":"2021","unstructured":"Jiang Y-H, Jhang J-F, Hsu Y-H, Ho H-C, Wu Y-H, Kuo H-C. Urine biomarkers in ESSIC type 2 interstitial cystitis\/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm. Sci Rep. 2021;11(1):914. https:\/\/doi.org\/10.1038\/s41598-020-80131-5","journal-title":"Sci Rep"},{"issue":"12","key":"6590_CR41","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s11255-013-0535-3","volume":"46","author":"L Wang","year":"2014","unstructured":"Wang L, Han X, Chen C, Ma Y, Hai B. Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder. Int Urol Nephrol. 2014;46(12):2251\u20138. https:\/\/doi.org\/10.1007\/s11255-013-0535-3","journal-title":"Int Urol Nephrol"},{"issue":"10","key":"6590_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076706","volume":"8","author":"H-T Liu","year":"2013","unstructured":"Liu H-T, Jiang Y-H, Kuo H-C. Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy. PLoS One. 2013;8(10):e76706. https:\/\/doi.org\/10.1371\/journal.pone.0076706.","journal-title":"PLoS One"},{"issue":"1","key":"6590_CR43","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.juro.2012.08.187","volume":"189","author":"T Antunes-Lopes","year":"2013","unstructured":"Antunes-Lopes T, Pinto R, Barros SC, Botelho F, Silva CM, Cruz CD, et al. Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol. 2013;189(1):359\u201365. https:\/\/doi.org\/10.1016\/j.juro.2012.08.187.","journal-title":"J Urol"},{"issue":"6","key":"6590_CR44","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00192-013-2047-2","volume":"24","author":"G Vijaya","year":"2013","unstructured":"Vijaya G, Cartwright R, Derpapas A, Gallo P, Fernando R, Khullar V. Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder. Int Urogynecol J. 2013;24(6):983\u20139. https:\/\/doi.org\/10.1007\/s00192-013-2047-2","journal-title":"Int Urogynecol J"},{"issue":"5","key":"6590_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064696","volume":"8","author":"M Silva-Ramos","year":"2013","unstructured":"Silva-Ramos M, Silva I, Oliveira O, Ferreira S, Reis MJ, Oliveira JC, et al. Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome. PLoS One. 2013;8(5):e64696. https:\/\/doi.org\/10.1371\/journal.pone.0064696.","journal-title":"PLoS One"},{"issue":"8","key":"6590_CR46","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00192-012-1991-7","volume":"24","author":"KJ Cho","year":"2013","unstructured":"Cho KJ, Kim HS, Koh JS, Kim JC. Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics. Int Urogynecol J. 2013;24(8):1265\u201371. https:\/\/doi.org\/10.1007\/s00192-012-1991-7","journal-title":"Int Urogynecol J"},{"issue":"5","key":"6590_CR47","first-page":"667","volume":"105","author":"H-T Liu","year":"2010","unstructured":"Liu H-T, Chen C-Y, Kuo H-C. Urinary nerve growth factor in women with overactive bladder syndrome. BJU Int. 2010;105(5):667\u201371.","journal-title":"BJU Int"},{"issue":"8","key":"6590_CR48","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00192-011-1409-4","volume":"22","author":"G Ghoniem","year":"2011","unstructured":"Ghoniem G, Faruqui N, Elmissiry M, Mahdy A, Abdelwahab H, Oommen M, et al. Differential profile analysis of urinary cytokines in patients with overactive bladder. Int Urogynecol J. 2011;22(8):953\u201361. https:\/\/doi.org\/10.1007\/s00192-011-1409-4","journal-title":"Int Urogynecol J"},{"issue":"10","key":"6590_CR49","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00192-009-0945-6","volume":"20","author":"P Tyagi","year":"2009","unstructured":"Tyagi P, Barclay D, Zamora R, Yoshimura N, Peters K, Vodovotz Y, et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urogynecol J. 2009;20(10):1231\u20139. https:\/\/doi.org\/10.1007\/s00192-009-0945-6","journal-title":"Int Urogynecol J"},{"issue":"6","key":"6590_CR50","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1016\/j.juro.2008.01.119","volume":"179","author":"H-T Liu","year":"2008","unstructured":"Liu H-T, Kuo H-C. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol. 2008;179(6):2270\u20134. https:\/\/doi.org\/10.1016\/j.juro.2008.01.119.","journal-title":"J Urol"},{"issue":"4","key":"6590_CR51","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/nau.20741","volume":"29","author":"H-C Kuo","year":"2010","unstructured":"Kuo H-C, Liu H-T, Chancellor MB. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodyn. 2010;29(4):482\u20137. https:\/\/doi.org\/10.1002\/nau.20741.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"6590_CR52","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.eururo.2008.04.037","volume":"56","author":"H-T Liu","year":"2009","unstructured":"Liu H-T, Chancellor MB, Kuo H-C. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol. 2009;56(4):700\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2008.04.037.","journal-title":"Eur Urol"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-026-06590-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-026-06590-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-026-06590-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:36:14Z","timestamp":1791466574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-026-06590-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["6590"],"URL":"https:\/\/doi.org\/10.1007\/s00192-026-06590-y","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The review was registered in PROSPERO (ID: CRD420251026279) and was amended on a later date for extending the period included in the review. Ethical approval is not required for this systematic review because it does not involve new data collection from human participants, relying exclusively on publicly available and previously published data, and thus meets national and institutional criteria for exemption from ethics committee review.","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any conflict of interest regarding the publication of this systematic review.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}